サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1733328

ヘルスケアナノテクノロジー（ナノ医療）の世界市場規模：モダリティ別、適応症別、用途別、地域範囲別および予測

Global Healthcare Nanotechnology (Nanomedicine) Market Size By Modality (Treatment, Diagnostics), By Indication (Clinical oncology, Infectious diseases), By Application (Drug Delivery, Regenerative medicine), By Geographic Scope And Forecast

出版日
ページ情報
英文 202 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.76円
ヘルスケアナノテクノロジー（ナノ医療）の世界市場規模：モダリティ別、適応症別、用途別、地域範囲別および予測
出版日: 2025年05月13日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ヘルスケアナノテクノロジー（ナノ医療）の市場規模と予測

ヘルスケアナノテクノロジー（ナノ医療）市場規模は、2024年に2,203億4,000万米ドルと評価され、2026～2032年にかけて13.14%のCAGRで成長し、2032年には5,529億3,000万米ドルに達すると予測されています。

世界のヘルスケアナノテクノロジー（ナノ医療）市場は、規制の枠組みが改善するにつれて成長しています。技術開発の開拓と研究投資の増加が市場拡大の原動力となります。COVID-19はナノ医療セグメントに比較的良い影響を与えました。これは、がん様疾患の治療に使用されるナノ医療に対するニーズが急増したことに起因します。さらに、市場参入企業は、あらゆるセグメントでナノ医療の研究開発活動が活発化した結果、材料や資源への支出が増加しています。世界のヘルスケアナノテクノロジー（ナノ医療）市場レポートは、市場の全体的な評価を記載しています。主要セグメント、動向、市場促進要因、抑制要因、競合情勢、市場で重要な役割を果たしている要因などを包括的に分析しています。

世界のヘルスケアナノテクノロジー（ナノ医療）市場の定義

ナノテクノロジーは、21世紀における最も有望な技術の1つです。ナノテクノロジーは、技術開発が0.1～100nmのスケールで行われる場合に使用される用語です。ナノ医療は通常、ナノテクノロジーの一セグメントであり、診断、予防、病気の治療、さらには組織や臓器の再生のための分子レベルでの医療開発を含みます。ナノテクノロジーは、21世紀における最も有望な技術のひとつです。ナノテクノロジーとは、技術開発が0.1～100nmのスケールで行われる場合に使われる用語です。ナノ医療は通常、ナノテクノロジーの一セグメントであり、診断、予防、病気の治療、さらには組織や臓器の再生のための分子レベルでの医療開発に関わる。

人間の健康を維持・改善することは、その一助となります。整形外科的問題、血液、肺、がん、パーキンソン病、アルツハイマー病、糖尿病、神経系、循環器系に関連する病気など、生命を脅かすさまざまな病気に対して、ナノ医療は強力な解決策を記載しています。これらはプログラム可能な特性を持つ多機能薬であり、ナノデバイスやナノ粒子を用いた分子レベルでの生物学的システムのモニタリング、構築、修復、制御といった応用を見出すのに役立ちます。デンドリマー、ミセル、ナノ結晶、フラーレン、ビロゾームナノ粒子、ナノ細孔、リポソーム、ナノロッド、ナノエマルション、量子ドット、ナノロボットなど、さまざまな技術によって支えられています。

ナノ医療は、がん治療の有望な手段となる可能性があります。この医療研究の成長セグメントは、がんを含むさまざまな病気に対して、より個人に合った治療法を発見するために、しばしばウォンツとなっています。ナノ医療は、ナノスケールで物質の性質を持つという利点から、標準的な治療法よりも効果が高く、副作用の少ない革新的な薬剤の開発が期待されています。したがって、病気の診断、治療、予防を強化するための技術進歩の必要性が、ヘルスケアナノテクノロジー（ナノ医療）市場の主要促進要因であることが判明しています。がんの場合、ナノ医療は、がんの診断と治療の現在の方法から有望な変化をもたらします。

世界のヘルスケアナノテクノロジー（ナノ医療）市場概要

ナノ医療には、病気の検出、診断、治療方法に関する現在のシナリオを完全に変化させ、革命を起こす可能性があります。ドラッグデリバリーなどの革新的な技術の出現により、ナノ医療にはいくつかの利点があり、世界のヘルスケアナノテクノロジー（ナノ医療）市場を大幅に押し上げると考えられます。政府の資金援助や支援の増加は、市場の需要増加につながるとともに、安全で費用対効果の高い治療法が市場の成長を支えることになります。

ナノ医薬品のライセンシングの増加や新興国におけるヘルスケア施設の成長は、市場成長のための十分な機会の創出に役立っています。疾患の早期診断、予防的介入、慢性疾患や急性疾患の予防に関連する応用を含む技術の進歩は、この市場の成長を後押しすると予想されます。ナノテクノロジーは、より大きな構造や化学品をナノメートルスケールで小型化することで、薬剤投与に急速な革命をもたらし、この技術の採用に影響を与えています。

政府組織からの資金提供の増加によるナノロボティクスの期待される開発は、市場の可能性を誘発すると予想されます。ナノ分子と関連技術に支えられた製品の潜在的なパイプラインは、潜在的な成長手段で市場を牽引すると予想されます。DNA折り紙のヘルスケア用途への利用が、世界のヘルスケアナノテクノロジー（ナノ医療）市場の成長を牽引します。しかし、長い承認プロセスとナノ医療に関連するリスク（環境への影響）が市場の成長を抑制します。

目次

第1章 世界のヘルスケアナノテクノロジー（ナノ医療）市場の導入

  • 市場概要
  • 調査範囲
  • 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

  • データマイニング
  • バリデーション
  • 一次資料
  • データソース一覧

第4章 世界のヘルスケアナノテクノロジー（ナノ医療）市場展望

  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • ポーターのファイブフォースモデル
  • バリューチェーン分析

第5章 ヘルスケアのナノテクノロジー（ナノ医療）の世界市場：モダリティ別

  • 概要
  • 治療
  • 診断

第6章 ヘルスケアナノテクノロジー（ナノ医療）の世界市場：適応症別

  • 概要
  • 臨床腫瘍学
  • 感染症
  • 臨床心臓病学
  • 整形外科
  • 神経学
  • 泌尿器科
  • 眼科
  • 免疫学
  • その他

第7章 世界のヘルスケアナノテクノロジー（ナノ医療）市場：用途別

  • 概要
  • ドラッグデリバリー
  • 再生医療
  • インプラント
  • 診断
  • イメージング
  • ワクチン
  • その他

第8章 ヘルスケアナノテクノロジー（ナノ医療）の世界市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • その他の欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他のアジア太平洋
  • その他
    • ラテンアメリカ
    • 中東・アフリカ

第9章 世界のヘルスケアナノテクノロジー（ナノ医療）市場の競合情勢

  • 概要
  • 各社の市場ランキング
  • 主要開発戦略

第10章 企業プロファイル

  • Sanofi SA
  • Abbott
  • Pfizer Inc.
  • CombiMatrix Corporation
  • GE Healthcare
  • Celgene Corporation
  • Johnson & Johnson Services, Inc.
  • Luminex Corporation
  • Merck & Company, Inc.
  • Nanosphere
  • Nanosphere, Inc.
  • Bristol-Myers Squibb
  • Leadient BioSciences Inc.
  • Teva Pharmaceutical Industries Ltd
  • Mallinckrodt plc.

第11章 主要開発

  • 製品上市/開発
  • 合併と買収
  • 事業拡大
  • パートナーシップと提携

第12章 付録

  • 関連調査
目次
Product Code: 63885

Healthcare Nanotechnology (Nanomedicine) Market Size And Forecast

Healthcare Nanotechnology (Nanomedicine) Market size was valued at USD 220.34 Billion in 2024 and is projected to reach USD 552.93 Billion by 2032, growing at a CAGR of 13.14% from 2026 to 2032.

The Global Healthcare Nanotechnology (Nanomedicine) Market is growing as the regulatory framework improves. Growth in technological developments, as well as an increase in research investment, will drive market expansion. COVID-19 has had a relatively good impact on the nanomedicine sector. This was attributable to a surge in the need for nanomedicines used to treat cancer-like disorders. Furthermore, market participants have seen a growth in spending on materials and resources as a result of an increase in nanomedicine R&D activities in all areas. The Global Healthcare Nanotechnology (Nanomedicine) Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Healthcare Nanotechnology (Nanomedicine) Market Definition

Nanotechnology is one of the foremost promising technologies in the 21st century. Nanotechnology may be a term used when technological developments occur at a 0.1 to 100 nm scale. Nanomedicine is usually a branch of nanotechnology as it involves medicine development at a molecular scale for diagnosis, prevention, treatment of diseases, and even regeneration of tissues and organs. Nanotechnology is one of the foremost promising technologies in the 21st century. Nanotechnology may be a term used when technological developments occur at a 0.1 to 100 nm scale. Nanomedicine is usually a branch of nanotechnology as it involves medicine development at a molecular scale for diagnosis, prevention, treatment of diseases, and even regeneration of tissues and organs.

Preserving and improving human health helps in doing so. For various life-threatening diseases like orthopedic problems, diseases related to blood, lungs, cancer, Parkinson's, Alzheimer's, diabetes, neurological, and cardiovascular system Nanomedicine offers a strong solution. These are multifunctional drugs with programmable properties which help in finding the applications such as monitoring, construction, repair, and control of biological systems at the molecular level using nanodevices and nanoparticles. Development of a replacement nanomedicine takes several years which is supported by various technologies like dendrimers, micelles, nanocrystals, fullerenes, virosome nanoparticles, nanopores, liposomes, nanorods, nanoemulsions, quantum dots, and nanorobots.

Nanomedicine may be a promising mode of cancer treatment. This growing field of medical research is often wont to discover a better-personalized treatment for a good range of diseases, including cancer. As nanomedicine promises to develop innovative drugs which have greater efficacy and lesser side effects than standard therapies because of its benefits as it has the properties of matter at the nanoscale. The necessity for technological advancements to reinforce disease diagnosis, treatment, and prevention is thus found to be the main driver for the Healthcare Nanotechnology (Nanomedicine) Market. Within the case of cancers, nanomedicine offers promising changes from the present methods of diagnosing and treating cancer.

Global Healthcare Nanotechnology (Nanomedicine) Market Overview

Nanomedicines have the potential which can fully change or revolutionalize the current scenario of detection of disease, diagnosis, and treatment methods. With the emergence of innovative technologies such as drug delivery, and also there are several benefits of nanomedicine that will significantly boost the Global Healthcare Nanotechnology (Nanomedicine) Market. Rising government funding and support will lead to an increase in demand for the market as well as its safe and cost-effective therapies will support the market growth.

The increasing out-licensing of nano drugs and the growth of healthcare facilities in emerging economies help in creating an ample amount of opportunities for market growth. Technological advancements including relevant applications in early disease diagnosis, preventive intervention, and prophylaxis of chronic also as acute disorders are expected to bolster growth in this market. Nanotechnology involves The miniaturization of larger structures and chemicals at a nanometric scale involves Nanotechnology rapidly revolutionized drug administration, thus influencing the adoption of the technology.

Expected developments in nanorobotics due to the increase in funding from the govt organizations are expected to induce potential in the market. The potential pipeline of products supported by the nano molecules and associated technologies is anticipated to drive the market with potential avenues of growth. Utilization of DNA origami for healthcare applications driving the growth of the Global Healthcare Nanotechnology (Nanomedicine) Market. However, the long approval process and risks related to nanomedicine (environmental impacts) restrain the market growth.

Global Healthcare Nanotechnology (Nanomedicine) Market Segmentation Analysis

The Global Healthcare Nanotechnology (Nanomedicine) Market is segmented on the basis of Modality, Indication, Application, And Geography.

Healthcare Nanotechnology (Nanomedicine) Market, By Modality

  • Treatment
  • Diagnostics

Based on Disease, The market is bifurcated into Treatment and Diagnostics. The Treatment segment holds the largest market share among the others and is anticipated to stay dominant during the projected timeline, owing to technological breakthroughs in nanomedicines, increased nanomedicine adoption, rising chronic disease incidence rates, and an increase in the number of advanced and effective product launches.

Healthcare Nanotechnology (Nanomedicine) Market, By Indication

  • Clinical oncology
  • Infectious diseases
  • Clinical cardiology
  • Orthopedics
  • Neurology
  • Urology
  • Ophthalmology
  • Immunology
  • Others

Based on Application, The market is bifurcated into Clinical oncology, Infectious diseases, Clinical cardiology, Orthopedics, Neurology, Urology, Ophthalmology, Immunology, and Others. The Clinical oncology category was the largest category contributing to the growing market and is expected to maintain its dominance during the projected timeline, owing to an increase in the number of oncology disorders and rising disposable income. In the subject of oncology, nanomedicine provides intriguing alternatives to current cancer treatment and diagnosis approaches. The use of nano-based cancer medicines and diagnostics has made significant progress, and numerous new breakthroughs are currently in the works. Nanobiotix, a clinical-stage nanomedicine company, received CE approval in April 2019 for Hensify (NBTXR3), which is an aqueous suspension of crystalline hafnium oxide or HfO2 nanoparticles intended for injection directly into the tumor prior to a patient's first classic radiation therapy treatment of advanced soft tissue sarcoma.

Healthcare Nanotechnology (Nanomedicine) Market, By Application

  • Drug delivery
  • Regenerative medicine
  • Implants
  • Diagnostic
  • Imaging
  • Vaccines
  • Others

Based on Application, The market is bifurcated into Drug Delivery, Regenerative medicine, Implants, Diagnostic, Imaging, Vaccines, and Others. The Drug delivery sector was the largest contributor to the international market and is expected to persist dominant throughout the projected period, owing to a rise in the frequency of diseases like cancer and the COVID-19 virus, as well as a rise in awareness of the applications of nanomedicines.

Healthcare Nanotechnology (Nanomedicine) Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World
  • On the basis of Regional Analysis, The Global Healthcare Nanotechnology (Nanomedicine) Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America accounts for the maximum market share in this segment. The primary drivers driving market growth in the United States include technology improvements along with applicable applications in early illness detection, preventative intervention, and prevention of chronic and acute disorders, which are likely to drive market expansion. According to the CDC, heart disease accounted for one in every four fatalities in the United States in 2021. Coronary heart disease is the largest cause of death due to cardiac disease in the United States, accounting for 360,900 fatalities, and is followed by stroke (805,000). This high burden may result in a large need for particular therapeutic nano vectors, nanostructured stents, and tissue regeneration implants.
  • Furthermore, various R&D efforts on nanotechnology-based medications and diagnostics are underway in the country, which may fuel market expansion. For instance, in January 2020, Stanford University researchers produced a medication coated with nanoparticles that slows the progression of atherosclerosis in rats by lowering plaque deposition in their arteries without generating negative side effects. However, Asia-Pacific is predicted to develop at the fastest rate over the forecast period. Furthermore, Japan and China are projected to grow at a rapid CAGR in the Asia-Pacific nanomedicine market, owing to improvements in healthcare infrastructure, an increase in the number of health facilities coupled with smart instruments, the development of the R&D sector, an increase in healthcare reforms, and adoption of advanced technologies of nanomedicines.

Key Players

The "Global Healthcare Nanotechnology (Nanomedicine) Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Sanofi SA, Abbott, Pfizer Inc., CombiMatrix Corporation, GE Healthcare, Celgene Corporation, Johnson & Johnson Services, Inc., Luminex Corporation, Merck & Company, Inc., Nanosphere, Inc., Bristol-Myers Squibb, Leadient BioSciences Inc., Teva Pharmaceutical Industries Ltd, Mallinckrodt plc. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • January 2022 - NaNotics LLC has formed a research partnership with the Mayo Clinic to create a NaNot which addresses the soluble form of PD-LI, a tumor-generated immunological inhibitor.
  • December 2021 - Acura NanoMedicine Inc has announced the development of a nanotechnology-based approach to reduce medication resistance and revitalize cancer treatments.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET, BY MODALITY

  • 5.1 Overview
  • 5.2 Treatment
  • 5.3 Diagnostics

6 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET, BY INDICATION

  • 6.1 Overview
  • 6.2 Clinical oncology
  • 6.3 Infectious diseases
  • 6.4 Clinical cardiology
  • 6.5 Orthopedics
  • 6.6 Neurology
  • 6.7 Urology
  • 6.8 Ophthalmology
  • 6.9 Immunology
  • 6.10 Others

7 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET, BY APPLICATION

  • 7.1 Overview
  • 7.2 Drug delivery
  • 7.3 Regenerative medicine
  • 7.4 Implants
  • 7.5 Diagnostic
  • 7.6 Imaging
  • 7.7 Vaccines
  • 7.8 Others

8 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Sanofi SA
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Abbott
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Pfizer Inc.
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 CombiMatrix Corporation
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 GE Healthcare
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Celgene Corporation
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Johnson & Johnson Services, Inc.
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Luminex Corporation
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Merck & Company, Inc.
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Nanosphere
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments
  • 10.11 Nanosphere, Inc.
    • 10.11.1 Overview
    • 10.11.2 Financial Performance
    • 10.11.3 Product Outlook
    • 10.11.4 Key Developments
  • 10.12 Bristol-Myers Squibb
    • 10.12.1 Overview
    • 10.12.2 Financial Performance
    • 10.12.3 Product Outlook
    • 10.12.4 Key Developments
  • 10.12 Leadient BioSciences Inc.
    • 10.12.1 Overview
    • 10.12.2 Financial Performance
    • 10.12.3 Product Outlook
    • 10.12.4 Key Developments
  • 10.13 Teva Pharmaceutical Industries Ltd
    • 10.13.1 Overview
    • 10.13.2 Financial Performance
    • 10.13.3 Product Outlook
    • 10.13.4 Key Developments
  • 10.14 Mallinckrodt plc.
    • 10.14.1 Overview
    • 10.14.2 Financial Performance
    • 10.14.3 Product Outlook
    • 10.14.4 Key Developments

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

  • 12.1 Related Research